VirtualScopics Posts Q1 Financials

Matthew Skoufalos | | Radiology Business | Business Intelligence
Quantitative imaging provider VirtualScopics, Inc. announced its financials today. As compared with revenues of $3.6 million in the first quarter of 2011, its $3.7 million in revenues were up 2 percent in the first quarter of 2012. At $613,544, net losses for the first quarter of 2012 were up 33 percent year-over-year (as compared with net losses of $200,381 in the first quarter of 2011). VirtualScopics President and CEO Jeff Markin commented that despite the quarter being “the most active” in terms of image processing, that company needed to focus on new sales and expanding its strategic alliances.

Matthew Skoufalos

Related Content

Orano Med breaks ground on $265M thorium production site
Image-interpretation market scoreboard: Radiologists 72%, others 28%
Lantheus lands rights to budding radiopharmaceuticals for initial outlay of $35M
17 short-term strategies to address the national radiologist shortage
‘SR’ onboards another independent practice, its 1st in the Natural State
Analysis: Allied radiology professionals generate millions of dollars per year in indirect revenues alone

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.